Aquavit Pharmaceuticals has invested in proprietary technologies for more than a decade, building an intellectual-property portfolio at the intersection of personalized medicine, intelligent treatment systems, pharmaceutical preparation, microchannel delivery, skin health, biologics and AI-enabled healthcare.
A portfolio developed as interconnected platforms rather than isolated patents.
Granted protection for the personalized treatment platform in Europe (2016) and the United States (2017), from a family whose earliest priority date is January 2011; further United States grants covering microchannel delivery of bioactive compositions, generation of immune responses, and injectable compositions; an international publication covering delivery of bioactive compositions and formulations to the skin; and pending applications across oncology, dermatology and combination therapy.
Each platform is capable of supporting multiple products, indications, delivery systems and strategic partnerships. Technologies developed under this estate have been translated into commercial products in professional use internationally.
Aquavit's architecture governs what is recommended, what is prepared, how it is delivered, and what is learned from the result. Discovery-stage intelligence shortens a research program; this extends through to the patient and back.
The architecture developed through MAV-403, Aquavit’s Big Data intelligence engine, and APOLLO™ — the Personalized Injection Treatment Optimizer, carried internally as program PITO-001, with an independent follow-on patent under PITO-002 extending the compounding platform to topical formulations and to output devices including the AQT series.
An analysis that ends in a report changes nothing. The system was designed to carry a conclusion through to what a patient actually receives, and then to learn from the outcome.
Each event is recorded against the individual patient, so the record deepens over time and informs subsequent treatment. The clinician configures which evidence sources apply and makes the treatment decision.
Outcomes return to data, informing the next decision. Technology detail
Aquavit builds a distinct engine for each part of the value chain, and adds to them as further parts are mapped. Each is proprietary, each is built for the problem it addresses, and each is designed to operate alongside the others rather than as a single general system.
Real-time, jurisdiction-specific regulatory clearance and reimbursement intelligence — allowing a specialty asset to move through the differing rules of every market, at scale.
Orchestrates distribution and demand across territories — expanding reach and supplier volume without channel conflict, so commercial growth compounds market by market.
Further engines are in development, each addressing a discrete function within development, registration, distribution or clinical practice. The intention is a body of proprietary intelligence covering the chain end to end, rather than a single system asked to do everything.
The estate supports a multidisciplinary development portfolio spanning neuroscience, oncology, medical dermatology, medical aesthetics and immunology — from commercial-stage systems to earlier-stage research programs.
DTX-021, a botulinum toxin type A approved in more than eight countries outside the United States and cleared to IND here, alongside AQT-004 and AQB-121, combination products pairing microchannel delivery with botulinum toxin.
Detail →ACK-122 and BCC-903 for actinic keratosis and basal cell carcinoma, developed with university medical center partners.
Detail →Programs in micro-skin-anesthesia, atopic dermatitis, plaque psoriasis, palmar hyperhidrosis and alopecia, differentiated by route of administration.
Detail →The AQT device series — eight configurations of the microchannel delivery platform, commercially designated AQUAGOLD® — alongside the APOLLO™ preparation platform and AQR-924 dermal augmentation.
Detail →AQV-1122, a single-use epidermal delivery device supporting self-administration of vaccines and biologics.
Detail →Exosome delivery, ophthalmic methods, allergic-reaction detection, cannabinoid delivery and injectable compositions.
Detail →A patent or a registration is a claim until a court says otherwise. Aquavit has taken that step, and continues to.
Following proceedings brought by Aquavit Pharmaceuticals against parties manufacturing and distributing counterfeit product, the United States District Court for the Southern District of New York entered judgment in the company's favor, adopting the Report and Recommendation of the Magistrate Judge in full.
The Court found trademark infringement, counterfeiting and defamation; awarded damages together with attorney fees and costs; imposed further sanctions for contemptuous conduct during the proceedings; and granted permanent injunctive relief.
The company had previously prevailed before the European Union Intellectual Property Office in a parallel trademark matter, and has pursued enforcement in more than one jurisdiction.
Creating intellectual property and registering it are the first two disciplines. Enforcing it is the third, and it is exercised as a matter of routine rather than exception.
Matter of public record. Enforcement is conducted on a continuing basis in the jurisdictions in which the company's rights are held.
The platforms were developed to be extended, and the pattern of the past fifteen years has been that each finds applications beyond the one it was built for. Work continues along these lines.
Applying the delivery platform where route of administration is the limiting factor on an otherwise sound therapeutic.
Extending the personalized preparation approach beyond injectables into topical and skincare applications.
New indications for the delivery platform, from IND through registration, in the divisions already established.
Combination approaches pairing biologic assets with proprietary preparation and delivery technologies.
The clinical record compounds as it grows, and becomes applicable to indications beyond those it was first built for.
Investigator-led studies and work with academic medical centers, including through the Institute for Botulinum Toxin Research.
The pattern has repeated: a platform is developed, protected, applied to one indication, and then found to apply to several more.
Microchannel delivery began as a dermatological technology and now underpins programs in oncology, immunology and neuroscience. The preparation platform began with injectables and now extends to topicals. That breadth is the growth case.